Terns Pharmaceuticals Stock In The News

TERN Stock  USD 3.18  0.27  7.83%   
Our overall analysis of Terns Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Terns Pharmaceuticals. The specific impact of Terns Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Terns Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Terns Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Terns Pharmaceuticals Backtesting and Terns Pharmaceuticals Hype Analysis.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

Terns Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
https://finance.yahoo.com/news/weight-loss-stock-could-skyrocket-140300063.html
 Neutral
Macroaxis News: globenewswire.com
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
https://www.globenewswire.com/news-release/2025/02/25/3031999/0/en/Terns-Pharmaceuticals-Provides-Program-Updates-and-Announces-Participation-at-TD-Cowen-45th-Annual-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
https://www.globenewswire.com/news-release/2025/02/24/3031517/0/en/Terns-Pharmaceuticals-Appoints-Andrew-Gengos-as-Chief-Financial-Officer.html
 Neutral
Macroaxis News: globenewswire.com
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
https://www.globenewswire.com/news-release/2025/02/20/3030084/0/en/Terns-Pharmaceuticals-Appoints-Robert-Azelby-to-Board-of-Directors.html
 Neutral
Macroaxis News: globenewswire.com
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
https://www.globenewswire.com/news-release/2025/02/05/3021571/0/en/Terns-Pharmaceuticals-to-Participate-in-the-Oppenheimer-35th-Annual-Healthcare-Life-Sciences-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
https://www.globenewswire.com/news-release/2025/02/03/3019856/0/en/Terns-Pharmaceuticals-Reports-Inducement-Grant-to-New-Employee-Under-Nasdaq-Listing-Rule-5635-C-4.html
 Bullish
Yahoo News
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
https://finance.yahoo.com/news/missed-viking-therapeutics-buy-weight-112100678.html
 Bullish
Yahoo News
Micron, Oracle are new Top Picks at Mizuho
https://finance.yahoo.com/news/micron-oracle-top-picks-mizuho-125947175.html
 Bullish
Investors Business Daily at Macroaxis
3 Biotech Stocks That Could Have Investors Grinning Soon
https://finance.yahoo.com/news/3-biotech-stocks-could-investors-175456049.html
 Bullish
Yahoo News
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
https://finance.yahoo.com/news/2-biotechs-beat-eli-lilly-133000362.html
 Neutral

Terns Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Terns and other traded companies coverage with news coverage. We help investors stay connected with Terns headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Terns Stock performance. Please note that trading solely based on the Terns Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Terns Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Terns Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Terns Pharmaceuticals noise-free hype analysis.
Terns Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Terns earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Terns Pharmaceuticals that are available to investors today. That information is available publicly through Terns media outlets and privately through word of mouth or via Terns internal channels. However, regardless of the origin, that massive amount of Terns data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Terns Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Terns Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Terns Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Terns Pharmaceuticals alpha.

Terns Largest EPS Surprises

Earnings surprises can significantly impact Terns Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-12
2024-09-30-0.32-0.280.0412 
2024-05-13
2024-03-31-0.34-0.30.0411 
2023-05-15
2023-03-31-0.27-0.31-0.0414 
2022-03-03
2021-12-31-0.63-0.560.0711 
2022-11-09
2022-09-30-0.52-0.440.0815 
2023-08-08
2023-06-30-0.34-0.250.0926 
View All Earnings Estimates

Terns Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Terns Pharmaceuticals Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Google News at Macroaxis
11th of March 2025
Terns Pharmaceuticals stock hits 52-week low at 3.27 - Investing.com
at news.google.com 
Google News at Macroaxis
3rd of March 2025
Terns Pharmaceuticals stock hits 52-week low at 3.54 - Investing.com India
at news.google.com 
Gurufocus Stories at Macroaxis
26th of February 2025
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq...
at gurufocus.com 
seekingalpha News
24th of February 2025
Terns Pharmaceuticals appoints new CFO
at seekingalpha.com 
Macroaxis News
18th of February 2025
Insider Trading
at MacroaxisInsider 
Google News at Macroaxis
13th of February 2025
Terns Pharmaceuticals stock hits 52-week low at 4.16 - Investing.com
at news.google.com 
Gurufocus Stories at Macroaxis
6th of February 2025
BlackRock, Inc. Increases Stake in Terns Pharmaceuticals Inc
at gurufocus.com 
Macroaxis News: globenewswire.com
5th of February 2025
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Scienc...
at globenewswire.com 
Macroaxis News: globenewswire.com
3rd of February 2025
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5...
at globenewswire.com 
Google News at Macroaxis
30th of January 2025
Acquisition by Burroughs Amy L. of 1075000 shares of Terns Pharmaceuticals at 4.64 subject...
at news.google.com 

Terns Pharmaceuticals Investors Sentiment

The influence of Terns Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Terns. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Terns Pharmaceuticals' public news can be used to forecast risks associated with an investment in Terns. The trend in average sentiment can be used to explain how an investor holding Terns can time the market purely based on public headlines and social activities around Terns Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Terns Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Terns Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Terns Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Terns Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Terns Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Terns Pharmaceuticals' short interest history, or implied volatility extrapolated from Terns Pharmaceuticals options trading.
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out Terns Pharmaceuticals Backtesting and Terns Pharmaceuticals Hype Analysis.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
0.035
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.